You're expecting the article to say something else, when the point of the article is clearly laid out in the headline itself. Which is that this particular case is not the 'odd one out', but common, or common enough in the drug industry. Obviously, the drug companies want to scapegoat this dude and avoid any negative press for the other times they bump up prices.

I agree with you that to make a distinction between legitimate and illegitimate price increases is needed. But then again, I'd say the fact that healthcare is a for-profit industry has already put the incentives in place necessary for anyone interested in dabbling on the dark side.